Intellia Therapeutics, Inc.
NTLA
Rank in Stocks
#6534
Intellia Therapeutics, Inc. is a biotechnology firm dedicated to advancing... Intellia Therapeutics, Inc. is a biotechnology firm dedicated to advancing therapeutic treatments through its expertise in genome editing. The company's pipeline includes several in vivo (administered within the body) programs. NTLA-2001 is currently undergoing a Phase 1 clinical trial for transthyretin amyloidosis, while NTLA-2002 targets hereditary angioedema. Additionally, Intellia is developing various other liver-focused therapies for conditions such as hemophilia A and B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo (processed outside the body) pipeline features NTLA-5001, a candidate for acute myeloid leukemia. The company is also progressing proprietary programs focused on creating engineered cell therapies to address diverse oncological and autoimmune disorders. At the core of Intellia's technology is the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has established multiple licensing and collaboration agreements. These include a partnership with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for treating sickle cell disease, and a co-development agreement with Regeneron Pharmaceuticals, Inc. for potential products against hemophilia A and B. The company also collaborates with Ospedale San Raffaele and holds a strategic alliance with SparingVision SAS to develop novel genomic medicines for ocular diseases, leveraging CRISPR/Cas9 technology. The company, initially known as AZRN, Inc., was founded in 2014 and operates from its headquarters in Cambridge, Massachusetts.
Share Price
$12.11
Last synced: 2026-11-09
Market Cap
$1.70B
Change (1 day)
6.70%
Change (1 year)
27.61%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Intellia Therapeutics, Inc. (NTLA)
Category
Healthcare
Operating Margin for Intellia Therapeutics, Inc. (NTLA)
Operating Margin as of November 2026 TTM: -711.66%
According to Intellia Therapeutics, Inc.'s latest financial reports, its current operating margin (TTM) is -711.66%. At the end of 2025 the company had an operating margin of -651.67%.
Operating Margin history for Intellia Therapeutics, Inc. from 2014 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -711.66% | 9.21% |
| 2025 | -651.67% | -29.40% |
| 2024 | -923.10% | -35.02% |
| 2023 | -1,420.51% | 61.60% |
| 2022 | -879.04% | 8.47% |
| 2021 | -810.37% | 244.09% |
| 2020 | -235.51% | -4.57% |
| 2019 | -246.78% | -17.35% |
| 2018 | -298.58% | 12.11% |
| 2017 | -266.32% | 36.47% |
| 2016 | -195.15% | -12.04% |
| 2015 | -221.86% | 0.00% |
| 2014 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.05% |
US
|
|
| -149.01% | -99.79% |
US
|
|
| 25.57% | -100.04% |
AU
|
|
| 31.23% | -100.04% |
BE
|
|
| 29.35% | -100.04% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Intellia Therapeutics, Inc.'s operating margin
What is Intellia Therapeutics, Inc.'s operating margin?
Intellia Therapeutics, Inc.'s operating margin is -711.66%, as of Nov 2026.
What was Intellia Therapeutics, Inc.'s operating margin in 2025?
In 2025, Intellia Therapeutics, Inc.'s operating margin was -651.67%, compared with -923.10% in 2024.
How has Intellia Therapeutics, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Intellia Therapeutics, Inc.'s operating margin was highest in 2020 (-235.51%) and lowest in 2023 (-1,420.51%).
How does Intellia Therapeutics, Inc.'s operating margin compare with similar companies?
Intellia Therapeutics, Inc.'s operating margin (-711.66%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.